NeurogesX, Inc. (NASDAQ: NGSX), a biopharmaceutical company based in the San Francisco Bay Area, is focused on developing effective treatments that relieve chronic pain and improve quality of life. NGX-4010, the company’s leading product candidate, could possibly revolutionize the treatment of neuropathic pain as a single application may provide months of relief. The product candidate is currently in Phase 3 clinical trials. For further information, visit the Company’s web site at www.neurogesx.com
- 17 years ago
QualityStocks
NeurogesX, Inc. (NASDAQ: NTII)
Tags Rodman & Renshaw
Related Post
-
Newton Golf Company Inc. (NASDAQ: NWTG) Unveils Lighter Shaft amid Women’s Golf Boom
Women make up roughly 28% of on-course golfers in the United States, a historic high.…
-
Soligenix Inc. (NASDAQ: SNGX) Makes Advancement in Proprietary Treatment for Behçet’s Disease
Behçet’s disease is more prevalent in countries along the Silk Road, including Türkiye, Iran and…
-
LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) Is ‘One to Watch’
LaFleur Minerals’ fully permitted Beacon Gold Mill, acquired in 2024 and refurbished by its previous…